Sponsored

Chimeric Therapeutics (ASX: CHM) to begin ADVENT-AML Phase 1B trial with GMP manufacturing completion

December 19, 2023 12:45 PM AEDT | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • GMP manufacturing of CHM 0201 NK cells has been completed to assist ADVENT-AML clinical trial.
  • CHM 0201 NK cells release testing has been concluded.
  • ADVENT-AML Phase 1B clinical trial will be conducted at The University of Texas MD Anderson Cancer Center.

Chimeric Therapeutics (ASX: CHM) has completed GMP manufacturing of CHM 0201 NK cells to aid the ADVENT-AML Phase 1B clinical study.

In the phase 1B clinical trial, the company will evaluate its off-the-shelf universal donor NK cell therapy, in combination with standard of care therapy for patients with newly diagnosed Acute Myeloid Leukemia (AML).

With the completion of GMP manufacturing and release testing of CHM 0201 NK cells, they are in transit to The University of Texas MD Anderson Cancer Center.

CHM shares up 5.5%

CHM shares jumped 5.56% to trade at AU$0.028 apiece at the time of writing on 19 December 2023, with market cap of AU$19.46 million.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.